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Introduction
Since the early isolation by Waksman of streptomycin from Streptomyces griseus, the
field of aminoglycoside research has expanded considerably through the development
of a variety of closely related compounds with well-defined antibacterial activities. From
a biochemical point of view, members of the aminoglycoside family consist of a similar
backbone, i.e. two or more aminosugars joined via a glycosidic linkage to a hexose (or
aminocyclitol) nucleus. The various compounds differ among themselves by the
aminosugars attached to the aminocyclitol (streptidine or 2-deoxystreptamine) nucleus.
Clinically important aminoglycoside antibiotics include streptomycin, neomycin, genta-
micin, sissomicin, tobramycin, netilmicin and amikacin. Although these agents exhibit
some differences in their antibacterial spectrum and clinical applications, their chemical
similarities give them similar properties, such as absorption, distribution, excretion and
toxicity. So while the host handles these related compounds in a similar way, bacteria
behave differently towards them (Korzeniowski & Hook, 1979; Waldvogel & Acar, 1978).
Heterogeneous bacterial susceptibility towards aminoglycosides can be explained by
at least three groups of mechanisms. Firstly, ribosomal alterations can modify the
binding site on the 30 s ribosomal fractions for streptidine-containing, but not for
2-deoxystreptamine-containing aminoglycosides, thereby preventing the attachment of
these aminoglycosides to their target (Hewitt, 1983). Secondly, changes in cell wall
permeability, and/or in the transmembrane transport mechanisms may prevent the
antibiotic from being carried against a gradient into the cytosol (Bryan, 1977). Lastly,
and undoubtedly the best-known resistance mechanism, is enzymic, in which a variety
of enzymes, some plasmid mediated, located within the periplasmic space, can neutralize
the antibiotics in situ by means of adenylylating, acetylating, and phosphorylating
mechanisms (Price et ai, 1981). It is also conceivable that the intrinsic resistance of some
bacterial species towards aminoglycosides is due to other and as yet unknown factors.
Before considering the future of the aminoglycoside antibiotics, I will briefly enumerate
their major clinical uses, their advantages and disadvantages, as well as the problems
encountered during their administration. Moreover, since ^ -lactam antibiotics have made
such considerable progress in recent years to provide compounds with a similar antibiotic
spectrum to aminoglycosides, I shall try to analyse with similar criteria their present
indications, advantages and disadvantages. Finally, I shall try to delineate what
improvements the clinician is expecting from future research in the field of aminoglycoside
antibiotics to improve their present profile.
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Clinical use of aminoglycosides
It is generally accepted that there are at present seven major indications for treatment
with aminoglycoside antibiotics, omitting the use of streptomycin in mycobacterial
diseases.
(1) Severe infections due to Gram-negative aerobic bacilli. Limitations in this
major indication include resistance to the aminoglycoside and susceptibility to
one of the less toxic compounds, such as ampicillin and cephalosporins. Usually
aminoglycosides are used to initiate therapy, but are often discontinued
thereafter in favour of other antibiotics.
(2) In combination with an anti-pseudomonal /?-lactam antibiotic for serious in-
fections caused by Pseudomonas aeruginosa in patients with apparently normal
defence mechanisms. Whether the /9-lactam compound is an absolute require-
ment in non-neutropenic patients has been discussed in detail recently by Young
(1982).
(3) Combined with a /Mactam antipseudomonal drug as empirical therapy in
febrile, leukopenic compromised hosts (Lau et al., 1977; Keating et al., 1979;
Love et al., 1979). Data from several laboratories and clinical studies have shown
that the best results are expected if the antibiotic combination is synergistic in
vitro (Schimpff et al., 1971; Klastersky et al., 1977). Poor results were obtained
if the offending micro-organism was resistant towards one of the antibiotics used
(Lau et al., 1977; Anderson et al., 1978), particularly in patients with ultimately
fatal disease. Since antibiotic susceptibility of the nosocomial organisms often
responsible for infections in compromised hosts varies greatly with time, clinical
setting, and geography, it is imperative to choose a /?-lactam antipseudomonal
compound and an aminoglycoside which fulfil local sensitivity requirements.
(4) Systemic staphylococcal infections. Based on in vitro data (Watanakunakorn &
Glotzbeckcr, 1974) and some experimental studies (Steigbigel et al., 1975),
several authors have suggested a combination of a /Mactamase-stable penicillin
and an aminoglycoside to treat such systemic infections. A collaborative clinical
study, however, has failed to show any significant benefit from such a
combination, except in drug addicts, where combination therapy caused a more
rapid clinical response without altering morbidity or mortality (Korzeniowski
& Sande, 1982). In other Staphylococcus aureus infections, aminoglycosides
alone or in combination have never appeared to be more effective than /?-lactam
antibiotics.
(5) Enterococcal bloodstream infections and resulting endocarditis. Antibiotic
combinations including penicillin G or vancomycin plus an aminoglycoside,
such as gentamicin, have been synergistic against most enterococci and are now
standard therapy.
(6) Infections following contaminated bowel and gynecological surgery can be
prevented to a large extent by the use of an antibiotic regimen aimed at
Gram-negative facultative aerobic bacilli and anaerobes. Thus, aminoglycosides
combined with a drug effective against Bacteroides fragilis (for example, clinda-
mycin, cefoxitin, or metronidazole), are highly effective, but other regimens with
a similar antibacterial spectrum are equally active, as discussed recently in detail
by Styrt & Gorbach (1982).
(7) Prophylaxis in bowel surgery (Clarke et al., 1977; Bartlett et al., 1978), in
cirrhotic patients with hepatic encephalopathy, and in immunocompromised,
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leukopenic patients (for review see Pizzo, 1983). Whether these indications are
all justified from an epidemiological point of view remains debatable. Paromo-
mycin has been used as a gastrointestinal disinfectant in shigellosis.
Advantages and disadvantages of aminoglycosides
The qualities of aminoglycoside antibiotics are self-evident. They have been in clinical use
for many years already, 20 in the case of gentamicin, and are therefore well known to
doctors. They cover an antibacterial spectrum for which there were few alternatives
available until a few years ago. Rapid progress in the field of antibiotic assay systems
has provided the clinician with the opportunity to follow serum levels during therapy,
adjusting dosages if necessary. This has in turn led to the development of computer
programs for adjusting aminoglycoside regimens with great accuracy by taking into
consideration many host-specific variables (Appel & Neu, 1978). Their great chemical
stability in vitro permits easy storage, and the absence of metabolic transformation in
the host permits their evaluation with simple pharmacokinetic models. Other advantages
include their rapid bactericidal effect, and the absence of an inoculum effect for bacteria
without drug-inactivating enzymes. Finally, their synergistic effect with /Mactam anti-
biotics against some Gram-negative bacilli, against many Ps. aeruginosa strains, and
against enterococci is valuable.
Clinical use of aminoglycosides has raised, however, over the years, a variety of
problems and questions which are still largely unsolved. First of all, as a reflection of
their polar polycationic charge, they are not absorbed after oral administration. Their
distribution within the host is limited, probably for similar reasons, their penetration into
the cerebrospinal fluid, bile and lung secretions being poor, and their cellular penetration
unpredictable or sometimes absent. Their biological disposition is altered by a variety
of factors, including age, renal function, presence of ascites, fever, underlying diseases,
and obesity. They can be inactivated under some conditions by carbenicillin and other
/?-lactam antibiotics (Noone & Pattison, 1971; Farchione, 1981). Although probably of
little clinical relevance except for patients in renal failure, this observation raises the
question whether host-specific polyanions present in interstitial fluid and inflamed tissues
might have similar effects. Changes in ionic composition, such as lowering of the pH
or increasing Ca1+ and Mg1+ concentrations, greatly decrease the antibacterial activities
of most aminoglycosides against Ps. aeruginosa and some other organisms (Vaudaux,
1981). Reversible binding to lysed polymorphonuclear leukocytes, as found in exudates,
can completely abolish their antibacterial effect (Vaudaux & Waldvogel, 1980). They have
a low therapeutic ratio, peak levels of 5 mg/1 for gentamicin for instance being considered
barely adequate, but 10 mg/1 almost in the toxic range. Therefore, their two major
toxicities, for the kidney and inner ear are still unsolved problems and limit their
widespread use. Finally, emergence of resistance has become a familiar and major
problem in many centres.
Alternatives to aminoglycoside treatment
During the last years, we have seen an explosive development in the field of /S-lactam
antibiotics, resulting in their use as alternative drugs in severe, Gram-negative infections.
Third-generation cephalosporins are poorly active indeed against Gram-positive organ-
isms, but encompass the same spectrum of antimicrobial activity as aminoglycosides
such as gentamicin, tobramycin, netilmicin and amikacin (Hewitt, 1983). In addition,
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the variety of third-generation cephalosporins available gives them some specific
additional advantages over aminoglycosides. Thus latamoxef (moxalactam) is also active
against obligate anaerobes, and third-generation cephalosporins are often fully active
against organisms resistant to earlier cephalosporins or aminoglycosides. Depending on
the infecting organism(s), treatment can be tailored by choosing a cephalosporin
characterized by broad- or narrow-spectrum activity. Furthermore, some compounds
present interesting pharmacokinetic characteristics, such as high penetration into the bile
(e.g. cefoperazone), or extremely prolonged elimination rates allowing single daily
parenteral administration (e.g. ceftriaxone). Their diffusion into some body compart-
ments can be particularly helpful, such as the good penetration of latamoxef (moxa-
lactam) across inflamed meninges into the cerebrospinal fluid, which makes it a useful
antibiotic in purulent meningitis (Schaad et al., 1981). Ototoxicity is absent and
nephrotoxicity extremely rare (Hewitt, 1983). Finally, some of them act synergistically
with aminoglycosides.
Putting all these advantages together, one wonders why third-generation cephalo-
sporins have not completely replaced aminoglycosides yet for the treatment of Gram-
negative infections. Indeed, their major therapeutic indications are similar to those
mentioned for aminoglycosides, and include severe Gram-negative infections due to
nosocomial organisms, such as bacteraemias, biliary tract infections and pneumonias,
particularly if the offending organism has been identified. For instance, Serratia spp. are
particularly susceptible to cefotaxime, and Ps. aeruginosa to cefsulodin. In addition,
latamoxef (moxalactam) has become a valuable member of the antibiotic armamentarium
for the treatment of purulent meningitis due to ampicillin-resistant Enterobacteriaceae
or to ampicillin-resistant Haemophilus influenzae (Schaad et al., 1981). Other important
indications for third-generation cephalosporins include infections due to aminoglycoside-
resistant Gram-negative organisms, and severe Gram-negative infections in patients with
renal insufficiency (Neu, 1982). Finally, they have also been used as empirical therapy
in febrile compromised hosts, most often in association with aminoglycosides (Hewitt,
1983).
In spite of their recent success, use of third-generation cephalosporins is not without
problems. Although the experience accumulated with these compounds extends only over
a few years, their efficacy has already been shown to vary with location and time, and
clearly reflects epidemiological changes in antibiotic susceptibilities (Neu, 1982). Some
cephalosporins are metabolized in the host, cefotaxime being for instance de-acetylated
in the liver. In vitro they occasionally show inoculum effects, and resistant variants can
be easily obtained in the laboratory. Their bactericidal activity is poor against Gram-
positive organisms, and is virtually absent against enterococci which have also sometimes
emerged as secondary invaders (Moellering, 1982). Finally, they have been held
responsible for a variety of adverse effects, such as hypersensitivity reactions, leukopenias,
platelet dysfunction, disulfiram effects and superinfections with Candida species and other
secondary invaders (Neu, 1982).
The future of aminoglycoside antibiotics
Although some of the newer /?-lactam compounds, including monobactam antibiotics and
some quinolone derivatives, will definitely offer future alternatives to aminoglycoside
therapy, it is unlikely that they will supplant it completely because of their own specific
problems. Nevertheless, the question can be asked how aminoglycosides could be further
improved to keep up with the rapid development of newer compounds. Firstly, the
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further development of less nephro- and ototoxic compounds would seem particularly
advisable, although from the data presently available I doubt whether within this family
toxicity can be completely prevented (Lerner et al., 1983). Co-administration of other
agents protecting the renal function, such as divalent cations, has been recently suggested
by new experimental data (Humes et al., 1983; Elliot et al., 1982). The discovery or
synthesis of non-toxic, non-aminoglycosidic inhibitors of inactivating enzymes would
increase their longevity by allowing their use even against some resistant organisms. Other
areas of research should include the development of new pharmacological preparations
of aminoglycosides with better diffusing capacities, such as increased diffusion across the
meninges, into inflammatory foci and possibly into phagocytes. In this respect, the
suggestions of packaging aminoglycosides into liposomes or of linking them covalently
to carrier molecules warrants careful experimental evaluation. Finally, efforts should be
made towards a better understanding of the bacterial oxygen-dependent, aminoglycoside-
uptake mechanism (Bryan, 1977), and its possible stimulation by non-toxic molecules.
It is conceivable that an induction of these mechanisms may allow aminoglycosides to
express their lethal intracellular effect at much smaller extracellular concentrations, thus
reducing potential nephro- or ototoxicity. Developments in these fields of aminoglycoside
research would ensure them a future similar to that presently seen with the /Mactam
compounds.
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